Document is current

Any future updates will be listed below

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

Crossref DOI link: https://doi.org/10.1186/s13075-014-0415-2

Published Online: 2014-08-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark